Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Non-use of intracranial pressure monitoring does not elevate ICH risk in ALF patients

19 May 2026

The use of invasive intracranial pressure monitoring (IICPM) in three high-volume liver transplant centres has declined over 10 years with no associated worsening of outcomes among patients with acute liver failure (ALF), according to a study.

Non-use of intracranial pressure monitoring does not elevate ICH risk in ALF patients

19 May 2026

Excessive IPFD ups risk of pancreatic diseases

10 May 2026 bởi

Excessive intrahepatic fat deposition (IPFD) appears to contribute to an increased risk of major pancreatic disease, suggests a recent study, noting the potential benefits of IPFD reduction in preventing pancreatitis and pancreatic cancer.

Excessive IPFD ups risk of pancreatic diseases

10 May 2026

Does anaesthetic technique affect cancer surgery outcomes?

06 May 2026 bởi

Propofol-based anaesthesia does not improve cancer-related outcomes in patients undergoing surgical resection of malignancies in the GA-CARES* trial.

Does anaesthetic technique affect cancer surgery outcomes?

06 May 2026

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

05 May 2026

Combination treatment with zibotentan and dapagliflozin results in a favourable safety profile and good tolerability in patients with compensated cirrhosis, but its effect on hepatic venous pressure gradient (HVPG) is inconclusive, a study has shown.

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

05 May 2026

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

23 Apr 2026 bởi

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and liraglutide, improves histologic outcomes in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) without compromising safety, reports a Singapore study.

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

23 Apr 2026

Two models of palliative care yield similar outcomes in end-stage liver disease

21 Apr 2026

Palliative care delivered by hepatologists yields similar improvements in quality of life (QoL) of patients with end-stage liver disease (ESLD) and is associated with greater patient satisfaction compared with palliative care delivered by specialists, according to a study.

Two models of palliative care yield similar outcomes in end-stage liver disease

21 Apr 2026

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

16 Apr 2026 bởi

Silymarin therapy combined with lifestyle interventions can reduce and normalize liver enzyme levels in patients with nonalcoholic fatty liver disease (NAFLD) and associated metabolic syndrome (MetS), a recent study has shown.

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

16 Apr 2026

Maladaptive EG tied to poor outcomes in patients with decompensated cirrhosis

15 Apr 2026

The risk of developing acute-on-chronic liver failure (ACLF) by 28 days and mortality by 90 days is increased among acutely decompensated cirrhosis (ADC) patients without ACLF who exhibit blood transcriptomic features of maladaptive emergency granulopoiesis (EG), suggests a study.

Maladaptive EG tied to poor outcomes in patients with decompensated cirrhosis

15 Apr 2026

Tin tức & Cập nhật

Xem bài viết Gan

Xem

Chuyên ngành:

Non-use of intracranial pressure monitoring does not elevate ICH risk in ALF patients

Non-use of intracranial pressure monitoring does not elevate ICH risk in ALF patients

Excessive IPFD ups risk of pancreatic diseases

Excessive IPFD ups risk of pancreatic diseases

Does anaesthetic technique affect cancer surgery outcomes?

Does anaesthetic technique affect cancer surgery outcomes?

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

Original New Drug Application Approvals by US FDA (16-31 March 2026)

Original New Drug Application Approvals by US FDA (16-31 March 2026)

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

Two models of palliative care yield similar outcomes in end-stage liver disease

Two models of palliative care yield similar outcomes in end-stage liver disease

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

Maladaptive EG tied to poor outcomes in patients with decompensated cirrhosis

Maladaptive EG tied to poor outcomes in patients with decompensated cirrhosis